Discovery of Selective, Covalent FGFR4 Inhibitors with Anti-tumor Activity in Models of Hepato-cellular Carcinoma

Hepatocellular carcinoma (HCC) accounts for 85–90% of primary liver cancer and is one of the most common forms of cancer worldwide.1 Aberrant signaling of the FGF19-FGFR4 pathway has been shown to ...